Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …

Thromboembolic events, including venous thromboembolism (VTE) and arterial
thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in …

Introduction Venous thromboembolism (VTE) is a leading cause of cardiovascular morbidity
and mortality. The majority of VTE events are hospital‐associated. In 2008, the …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

Coronavirus disease 2019 (COVID-19) affects the respiratory system of patients and is
characterized by pneumonia with hypoxemia. Hospitalized patients and particularly those …

Background Patients with COVID-19 infection are commonly reported to have an increased
risk of venous thrombosis. The choice of anti-thrombotic agents and doses are currently …

Background One year after the declaration of the coronavirus disease 2019 (COVID-19)
pandemic by the World Health Organization (WHO) and despite the implementation of …

There is a need to discriminate which COVID-19 inpatients are at higher risk for venous
thromboembolism (VTE) to inform prophylaxis strategies. The IMPROVE-DD VTE risk …

Background Through our work, we have demonstrated how clinical decision support (CDS)
tools integrated into the electronic health record (EHR) assist providers in adopting evidence …

Ambulatory patients with coronavirus disease 2019 (COVID-19) have a low risk of
developing venous thromboembolism (VTE), whereas hospitalization is associated with a …